開発中の末梢神経鞘腫瘍(神経線維肉腫)治療薬市場2021年

■ 英語タイトル:Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) - Drugs in Development, 2021

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC13210IDB)■ 発行会社/調査会社:Global Markets Direct
■ 商品コード:GMDHC13210IDB
■ 発行日:2021年12月
■ 調査対象地域:グローバル
■ 産業分野:医薬品
■ ページ数:567
■ レポート言語:英語
■ レポート形式:PDF
■ 納品方式:Eメール
■ 販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥296,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥592,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD6,000 ⇒換算¥888,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[開発中の末梢神経鞘腫瘍(神経線維肉腫)治療薬市場2021年]についてメールでお問い合わせはこちら
*** レポート概要(サマリー)***

本調査レポートでは、開発中の末梢神経鞘腫瘍(神経線維肉腫)治療薬市場について調査・分析し、末梢神経鞘腫瘍(神経線維肉腫)概要、治療薬開発、パイプライン概要、企業別のパイプライン、企業別の開発中製品、治療薬分析、標的別分析、作用機序別分析、投与経路別分析、分子タイプ別分析、治療薬開発に携わる企業など、以下の項目を掲載しております。
・末梢神経鞘腫瘍(神経線維肉腫)-概要
・末梢神経鞘腫瘍(神経線維肉腫)-治療薬開発
・パイプライン概要
・企業別のパイプライン
・企業別の開発中製品
・末梢神経鞘腫瘍(神経線維肉腫)-治療薬分析
・標的別分析
・作用機序別分析
・投与経路別分析
・分子タイプ別分析
・末梢神経鞘腫瘍(神経線維肉腫)-治療薬開発に携わる企業

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) – Drugs in Development, 2021

Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Drugs In Development, 2021, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 18, 4, 1, 4 and 1 respectively.

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

*** レポート目次(コンテンツ)***

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Overview
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Companies Involved in Therapeutics Development
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Drug Profiles
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Dormant Projects
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) – Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Number of Products by Stage and Target, 2021
Number of Products by Stage and Target, 2021 (Contd..1)
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Mechanism of Action, 2021 (Contd..1)
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by 3SBio Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Advenchen Laboratories LLC, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Aldeyra Therapeutics Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Apexian Pharmaceuticals Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Ascentage Pharma Group International, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by AstraZeneca Plc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by BeiGene Ltd, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bristol-Myers Squibb Co, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Calithera Biosciences Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Epizyme Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by F. Hoffmann-La Roche Ltd, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Jiangsu Hengrui Medicine Co Ltd, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Karyopharm Therapeutics Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Mirati Therapeutics Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Oncomatryx Biopharma SL, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Open Therapeutics LLC, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Otsuka Pharmaceutical Co Ltd, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pharma Mar SA, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Resverlogix Corp, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sino Biopharmaceutical Ltd, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Sorrento Therapeutics Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Vyriad Inc, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Dormant Projects, 2021
Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Discontinued Products, 2021


List of Figures
Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), 2021
Number of Products under Development by Companies, 2021
Number of Products by Top 10 Targets, 2021
Number of Products by Stage and Top 10 Targets, 2021
Number of Products by Top 10 Mechanism of Actions, 2021
Number of Products by Stage and Top 10 Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/



※注目の調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC13210IDB )"開発中の末梢神経鞘腫瘍(神経線維肉腫)治療薬市場2021年" (英文:Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) - Drugs in Development, 2021)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。